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Purpose:We aimed to develop a novel chemical cross-linker treatment for keratoconus
by reacting dicarboxylic acid spacer molecules and amine functional groups on protein
structure of the tissue using carbodi-imide chemistry. We propose this as an alternative
to conventional cross-linking treatment for keratoconus.
Methods: The study involved optimization of the cross-linker formulation. Mechanical
stiffness of ex vivo porcine and human corneas after application of the cross-linker was
measured. Histochemical analysis was performed to record changes in gross morphol-
ogy after cross-linker treatment on ex vivo porcine and human and in vivo rabbit
corneas. Terminal deoxynucleotidyl transferase–mediated dUTP-X nick-end-labeling
(TUNEL) staining was performed to study apoptotic effects of cross-linker. Cytotoxi-
city potential of cross-linker was evaluated by studying explant cultures for cellular
outgrowth and immunostaining assays on porcine and human corneas after treatment.
Results: We demonstrated a clinically relevant increase in stiffness in ex vivo experi-
ments using porcine and human cornea without removal of corneal epithelium. Histo-
logical analysis showed no change in gross morphology of cornea and no evidence
of apoptosis. In vivo treatment of rabbit eyes demonstrated initial thinning of corneal
epithelium that recovered after seven days although with abnormal regularity of cells.
Cellular outgrowth from corneal explant cultures after treatment further confirmed cell
survival after treatment.
Conclusions:This chemical cross-linkingof corneal tissuehaspotential advantagesover
current therapeutic options including lower cytotoxicity to stromal cells than ultraviolet
A treatment.
Translational Relevance: The cross-linker has potential to become a treatment for
keratoconus because it overcomes the need for procedures using specialized equip-
ment and ensures accessibility to large populations.
Introduction
Keratoconus is a progressive corneal disease, result-
ing in thinning and ectasia of the cornea with resultant
visual impairment.1 Although the underlying causes of
keratoconus are not fully understood, there is evidence
of a disruption of collagen fibrils, resulting in a change
in shape and thinning of the cornea2; it is proposed this
results from alterations in the corneal collagen lamellae
because of the loss of attachments between the colla-
gen fibrils and the proteoglycan matrix.3 Photochemi-
cal corneal collagen cross-linking is an FDA approved
therapy to treat keratoconus.2
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Conventional cross-linking is achieved by applica-
tion of riboflavin onto the cornea after removal of
the corneal epithelium, such that it penetrates the
corneal stroma, followed by activation with ultra-
violet A (UVA) irradiation. Riboflavin absorbs the
UVA energy and is activated to its triplet state where
photopolymerization results in covalent bonds between
collagen molecules or with proteoglycans within the
tissue. Exact macromolecular alterations in corneal
cross-linking with riboflavin are not fully understood,
but many ex vivo and in vivo studies have demon-
strated significant and clinically relevant increases in
the mechanical properties of the cornea.4,5 Histolog-
ically there is an increase in the collagen fiber diameter,
and biochemically there is evidence of some increase in
intrafibrillary collagen cross-links after riboflavin/UVA
corneal cross-linking.6 The effectiveness of corneal
cross-linking relies on the ability of the riboflavin to
penetrate into the corneal stroma, for there to be suffi-
cient oxygen present in the tissue and for the UVA to
have sufficient energy to activate the reactive oxygen
species. These prerequisites result in several limitations
and clinical risks. The UVA required is cytotoxic, and
it can take up to 12 months for keratocytes to repopu-
late the corneal stroma.7,8 UVA radiation will irrepara-
bly damage the corneal endothelium, and so, patients
with a cornea thinner than 400 μm cannot be treated
by this procedure.9,10 To achieve penetration of the
riboflavin requires removal of the corneal epithelium,
which is painful for the patient for several days after
treatment and increases risk of infection.11–13 Transep-
ithelial protocols have been evaluated but are not as
effective.4
We hypothesized that the use of a chemical cross-
linker would increase the mechanical properties of
the cornea while reducing or removing the limita-
tions and clinical risks associated with conventional
corneal cross-linking in keratoconus. Chemical cross-
linking would not require UVA exposure to form
chemical bonds between the proteins in the stroma. We
have used the well-known peptide cross-linking agents
1-ethyl-3-(3-dimethylaminopropyl) carbodi-imide HCl
(EDCI) and N-hydroxysuccinimide (NHS) which
activate carboxylate groups to react with primary
amine residues on amino acids by forming either
O-acylisourea or N-hydroxysuccinimidyl-ester inter-
mediates as a mechanism to strengthen the corneal
structure.14 We have included an eight carbon chain
dicarboxylic acid, octanedioic acid (ODA), as a cross-
linking spacer unit to provide a degree of control over
corneal stiffening and prevent the tissue becoming too
brittle.15 We demonstrated equivalent stiffening of ex
vivo porcine and human cornea to the conventional
UVA/riboflavin corneal cross-linking without requir-
ing removal of the corneal epithelium and with a lower
cytotoxicity in the cellular population of the cornea
compared with UVA treatment, including the delicate
and clinically vital corneal endothelium. In a prelim-
inary short-term in vivo study, the treatment caused
thinning of the epithelium at early time points and
recovery of the epithelial layer by day seven, although
with some impact on the regular thickness and arrange-
ment of the epithelial layer. No changes in other tissue
layers were observed histologically, and no apopto-
sis of cells was observed throughout the cornea using
TUNEL staining. Chemical cross-linking of corneal
tissue has potential to become a treatment for kerato-
conus with significant advantages over current thera-
peutic options.
Methods
Preparation of Cross-Linker Solution
All chemicals were from Sigma-Aldrich Corp.
(St. Louis, MO, USA), unless otherwise stated. The
cross-linker solution used was prepared as a mixture of
EDCI, NHS, and ODA. NHS (0.319 g) was dissolved
in 3.5 mL phosphate buffered saline solution (PBS),
and EDCI (0.537 g) was dissolved in 4.0 mL PBS.
NHS and EDCI are water soluble and dissolve after
some mixing to give clear, solutions. ODA (0.483 g)
was dissolved in 7.5 mL PBS with the addition of
2-(dimethylamino) ethanol (500 μL) and vigorous
mixing to give a clear solution. The three solutions were
added together and vortexed, giving a 0.2 M solution
with a 1:1:1 molar ratio of the three components. The
stock solution was further diluted with PBS to give
a 0.02 M solution. PBS or triton-X solution (16.7%,
5:30 v/v in PBS) instead of the cross-linking solution
was used as controls. Hexanedioic acid (HDA) and
decanedioic acid (DDA) were kindly provided ready
dissolved by SpheriTech Ltd., Runcorn, UK.
Treating the Tissue
Porcine
Whole porcine globes were obtained from the
abattoir (TanHouse Farm, Cheshire, UK) on the day
of slaughter. Eyes were trimmed, cleaned, and stored
in PBS (500mL) that contained penicillin/streptomycin
and amphotericin B (Gibco; Thermo Fisher Scien-
tific, Waltham, MA, USA), overnight at 4°C. The next
day whole eyes were placed into fresh cross-linking
solution, cornea side down stabilized on silicone rings
and incubated at 37°C for 15 minutes (Fig. 1A). After
treatment the eyes were rinsed in PBS before analysis.
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Figure 1. Analysis ofmechanical stiffness of the porcine and human cornea after cross-linker treatment. (A andB) Diagrammatic represen-
tation of the treatment of porcine eyes and human eyes, respectively, with the chemical cross-linker. (C) Mechanical stiffness of ex vivo
porcine cornea after treatment with dicarboxylic acids at 0.2 M concentration in comparison with PBS control. (D) Mechanical stiffness
of ex vivo porcine cornea after treatment with 0.2 M cross-linker solution mixture containing ODA for various time periods. (E) Compari-
son of the mechanical stiffness of porcine cornea treated with 0.2 M cross-linker solution mixture for 15 minutes, UVA/riboflavin using the
standard protocol and the PBS control. (F) Mechanical stiffness of human cornea treated with cross-linker solution mixture at 0.2 M and
0.02 M in comparison with PBS control.
We evaluated epithelial integrity of the porcine eyes
immediately before and after treatment using fluores-
cein staining (Supplementary Fig. S1).
UVA/riboflavin cross-linking: The epithelial layer
was scraped off using a scalpel blade and globes
immersed cornea side down into 3 mL of 0.1%
riboflavin solution (Aurolab, Madurai, India) for
30 minutes. The cornea was exposed to UV-A light
(Opto Xlink Corneal Crosslinking System; Opto
Electronica, São Paulo, Brazil; power 1.5 mW, inten-
sity 3.003 mW/cm2) for 30 minutes while applying
riboflavin solution (200 μL) to cornea every three
minutes.
Human
Human donor cadaver eyes were received from
Rotary Aravind International Eye Bank, Madurai,
India. Normal human cadaver globes were harvested
from the donor and processed within 24 to 30 hours
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after death.Keratoconus corneal central buttons (7mm
diameter) were obtained from patients who had severe
keratoconus and were undergoing deep anterior lamel-
lar keratoplasty procedure at theAravindEyeHospital,
Madurai, India. Informed consent from the patients
for the utilization of their corneas for research, insti-
tutional ethical committee approval of the Aravind
Eye Care System were obtained (approval number:
RES2015039CLI), and research followed the tenets
of the Declaration of Helsinki. Human cadaver eyes
were cleaned in PBS containing 2× penicillin and
streptomycin solution (Life Technologies, Carlsbad,
CA, USA), 50 μg/mL gentamicin (Life Technologies,),
1.25 μg/mL amphotericin B (Invitrogen, Carlsbad, CA,
USA). The cadaver eyes were supported in a small
dish with the epithelial surface facing up (Fig. 1B). A
10 mm trephine was placed over the corneal epithelial
surface to cover the central and para-central epithe-
lial surface and exclude the limbo-scleral region. The
chemical cross-linker (0.2 M and 0.02 M) was applied
within the trephine for 15 minutes at 37°C in a CO2
incubator. After the treatment, eyes were placed into
a beaker of fresh PBS for washing. For all the experi-
ments, PBS was used for untreated control.
It is important to note that the keratoconic tissue
was treated differently to whole cadaver eyes. The
keratoconus corneas were obtained from patients
undergoing deep anterior lamellar keratoplasty proce-
dures. They were treated with either concentration of
the cross-linker only on the epithelial side by invert-
ing the corneas in a 30 mm culture dish filled with
1 mL of the cross-linker solution. Care was taken to
avoid the spilling or overflowing of the cross-linker
solution into the stromal layer. After the 15 minutes
treatment inside the 37°C incubator, the keratoconus
corneas were washed with PBS, and the epithelium
was scraped off using a sterile scalpel. The stroma was
further processed in the same way as the stroma from
the cadaver cornea.
Mechanical Properties
Corneas were dissected from whole globes after
treatment ensuring a perimeter of sclera remained and
a dog-bone shape (10 mm long and 2 mmwide) sample
cut using a custom-made punch. The width and thick-
ness of the strip were measured using a digital calliper
(AbsoluteDigimatic,Mitutoyo, UK) and then the stiff-
ness of the porcine corneal strips was tested using a
Linkam Tensile Tester with T95 stage (Linkam Scien-
tific Instruments, Epsom, UK) with a 200 N load cell
at a strain rate of 100 μm/s (n = 3 per group). The
human corneal strips were tested (n = 5 per group)
using an Instron tensile tester (Instron Corporation,
Norwood, MA, USA) fitted with custom made tissue
holding clamps and a 50 N load cell at a strain rate of
100 μm/s. Stiffness of the cornea were calculated from
the linear part of the stress/strain graphs over a 5%
strain region.
Histology and Cell Culture
The tissue was prepared for histology using
standard procedures, and the details can be found
in the Supplementary Files. Explant cell cultures were
prepared from the treated tissue as detailed in the
supplementary Files.
Penetration Assay (Porcine and Human)
Whole globes (porcine and human) were obtained
and prepared for treatment as above. A 0.2 M concen-
tration of NHS-fluorescein (ThermoFisher Scientific,
St. Louis,MO,USA), wasmade up in PBS froma stock
solution dissolved in dimethyl sulfoxide. The treat-
ment solutions were applied to the prepared eyes for
15minutes at 37°C in aCO2 incubator. After treatment,
eyes were rinsed with PBS thoroughly before process-
ing and embedding for histology.
Animal Study
The animal study adhered to the ARVO Statement
for the Use of Animals in Ophthalmic and Vision
Research, and the NC3Rs (UK) and was performed
by The Laboratory Animal Center, National Taiwan
University College of Medicine (Institutional Animal
Care and Use Committee Approval No. 20170110).
Male, white New Zealand rabbits, 12 to 16 weeks
old, were weighed before treatment and ketamine
(40 mg/kg) anesthetic administered (n = 2 per condi-
tion and time point, total of six rabbits were used) and
topical 0.5% proparacaine hydrochloride instilled into
the eye (Bausch & Lomb, Rochester, NY, USA). An
eyelid speculum was placed in the left eye to keep it
open for treatment; the right eye served as a control.
In the left eye the lack of corneal staining with fluores-
cein was used to determine the integrity of the corneal
epithelium (fluorescein sodium 1% w/v; Bausch &
Lomb) and photographed. The fluorescein was washed
away with saline solution. The rabbit was orientated
to hold the treatment solution (0.2 M) in place for
15 minutes, after which the solution was drained, and
the eye was washed with copious amounts of saline
solution. The integrity of the epithelium was again
checked using 1% fluorescein and photographed, the
eyes were rinsed with saline solution, antibiotic drops
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Figure 2. Effect of the cross-linker on the gross morphology and cytotoxicity in the porcine cornea. (A) Representative micrographs of
H&E staining of porcine corneal tissue after cross-linking with the cross-linker solution mix (indicated as ODA) showing intact epithelium
and endothelium. UVA/riboflavin treated cornea has the epithelium removed and shows few keratocytes in the anterior stroma (scale bars:
100, 20, and 10 μm, respectively). (B) In situ apoptosis detection TUNEL assay demonstrating absence of any signs of apoptosis in treated
cornea, Triton-X treated tissue demonstrates apoptotic cells throughout the epithelium and endothelium (scale bars: 100, 20, and 10 μm,
respectively). Arrows indicate the apoptotic cells as shown by the dark brown staining in the nuclei of cells.
were administered in the treated eyes, and the rabbits
were allowed to recover.
The rabbits were assessed on alternate days to
observe any changes in animal behavior, determine
any adverse ocular findings resulting from chemical
cross-linking, and perform corneal photography. At the
relevant time points (one, three, and seven days after
treatment) rabbits were sedated, an eyelid speculum
was placed to keep eyes open, and the corneal epithe-
lium integrity was evaluated by fluorescein applica-
tion and photographed using a mounted microscope
(Carl Zeiss, Inc., White Plains, NY, USA; Exwave-
HAD; DSP 3CCD, color video camera, Sony, Tokyo,
Japan). The rabbits were euthanized using an overdose
of intravenous pentobarbital (100 mg/kg), and the
eyes were enucleated. The tissue was fixed in 4%
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Figure 3. Effect of the cross-linker on porcine endothelium.
Representative micrographs of alizarin red– and trypan blue–
stained porcine endothelium demonstrating an intact monolayer of
endothelial cells in the cross-linker–treated (indicated as ODA) and
PBS-treated cornea with evidence of mild damage to the endothe-
lial cells after treatment with UVA/riboflavin. Scale bar: 50 μm.
paraformaldehyde and processed for histological analy-
sis in hematoxylin and eosin (H&E) and TUNEL
staining. Epithelium thickness was measured using
ImageJ (NIH); three sections were taken from each
tissue per each time point to obtain six measurements.
Further details of methods can be found in the Supple-
mentary Materials.
Results
Chemical Cross-Linking of Tissue to Increase Stiffness
We demonstrated an increase in the stiffness of ex
vivo porcine and human corneal tissue using our dicar-
boxylic acid ester activated by a carbodi-imide chemi-
cal reaction. Initially cross-linking solutions containing
one of three dicarboxylic acids, DDA, ODA, andHDA
at a 0.2 M concentration were evaluated using ex vivo
porcine eyes. Results show a significant increase (P <
0.05) in the stiffness of 54.8% (DDA), 84.9% (ODA),
and 63.6% (HDA) in comparison to the untreated
control tissue (Fig. 1C). Of the three dicarboxylic acids
investigatedODAexhibited the highest increase in stiff-
ness, and, hence, cross-linker solution mixture contain-
ing ODA was used for the remaining experiments. In
these experiments the epithelium was not removed, but
it is important to consider that although the porcine
eyes were tested as soon as possible after death, the
epithelial cell tight junctions may have been compro-
mised to some extent postmortem.
We evaluated the influence of treatment times of
the ODA containing cross-linker mixture from 7.5 to
60 minutes and demonstrated there was no statisti-
cally significant difference over this range (Fig. 1D).
The highest increase in stiffness (84.5%), considered to
be clinically relevant, was obtained after 15 minutes
exposure and was therefore used as the treatment time
for all further experiments. Using our ex vivo porcine
model we compared the cross-linker with the conven-
tional clinical cross-linking method and demonstrated
that similar increases in stiffness were achieved between
the cross-linker solution mixture (0.2 M) treatment
(50.6%) and UVA/riboflavin treatment (46.1%), both
of which were significantly different (P < 0.05) than
untreated control tissue (Fig. 1E). In these tests the
epithelium was removed for the UVA/riboflavin treat-
ment but left intact for the chemical cross-linking treat-
ment.Whole human globes were treated with the cross-
linking solution at concentrations of 0.2 M and 0.02
M. We demonstrated a significant increase in stiffness;
125.5%, (P < 0.05) after treatment with 0.2 M cross-
linker and 156.3% (P < 0.05) after treatment with
0.02 M solution compared to untreated control tissue
(Fig. 1F). The difference between 0.2 M and 0.02 M
treated tissues was not statistically significant. We used
NHS-Fluorescein to assess penetration of the cross-
linker into the tissue. 0.2 M NHS-Fluorescein crossed
the corneal epithelial barrier, penetrated deep into the
stroma but did not reach the endothelium (Supplemen-
tary Fig. S2).
Safety Evaluation of the Chemical Cross-Linker
We analyzed the effect of the cross-linker on the
gross morphology of the cornea and its cytotoxicity on
cells of the corneal layers. We demonstrated that histo-
logical analysis of porcine cornea treated with 0.2 M
chemical cross-linker had the same gross morphology
as the untreated cornea. The epitheliumwas intact, and
there was no evidence of death of the stromal kerato-
cytes (Fig. 2A). In comparison, the UVA/riboflavin
treated cornea showed evidence of a lack of stromal
cells in the uppermost section of the tissue, suggest-
ing the treatment had killed the cells. Apoptosis of
the cells was evaluated using TUNEL staining and
demonstrated no evidence of apoptosis in the cross-
linker treated tissue or the control whereas Triton-X
treated samples demonstrated apoptotic cells (Fig. 2B)
as evidenced by the dark brown staining in the nuclei
of the cells in the epithelium and stroma. Similar
results were obtained for treated and untreated human
cadaver cornea (Supplementary Fig. S3). Alizarin
red/trypan blue staining was used to evaluate poten-
tial damage to the endothelium, which identifies the
cell membrane in intact cells and the permeability of
damaged cells,16 and in all samples a monolayer of
intact endothelial cells was observed (Fig. 3) over the
majority of the endothelium. To confirm the survival
of corneal cells after chemical cross-linker treatment
further, we harvested explants from treated corneal
tissue and allowed cells to grow out in culture using
standard procedures. Stromal cells were observed to
grow out from all tissue explants (porcine; Supple-
mentary Fig. S4, normal human; Fig. 4A and kerato-
conic human; Fig. 4B) after treatment. Human culture
expressed the stromal cell specific marker vimentin.
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Figure 4. Representative micrographs of stromal fibroblasts cultured from human cadaver (A) and keratoconic (B) corneal stromal tissue
after treatment with 0.2 M and 0.02M cross-linker solutionmixture (labeled as ODA) in comparison with PBS control demonstrating survival
of the cells. Expression of vimentin (green), the stromal fibroblast specific marker and actin network (red) is seen unperturbed even after
treatment with different concentrations of the cross-linker. Scale bars: 102 μm for 0.2 M images and 43.5 μm for 0.02 M and PBS images.
This is additional evidence to suggest that the cross-
linker has a lower cytotoxic effect to the stromal cells
in comparison with UVA treatment.
In Vivo Safety Analysis of the Cross-Linker
In vivo safety of the cross-linker treatment was
studied in a short-term rabbit model. At 24 hours after
treatment it was clear that the rabbits had some discom-
fort (Supplementary Fig. S5), and at this stage there
was thinning of the epithelium as assessed qualitatively
(Fig. 5). By three days the rabbits appeared unaffected
by the treatment and histologically the epithelium had
recovered by day seven (Supplementary Table S1),
although the regularity of the cells was abnormal. It
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Figure 5. Effect of the cross-linker on the gross morphology and cytotoxicity of rabbit cornea. Representative micrographs of H&E stained
samples (A and B) and TUNEL assay (C and D) of rabbit cornea, taken at days 1, 3, and 7 after treatment with 0.2 M cross-linker solution and
the PBS controls. H&E shows thinning of corneal epithelium; however, TUNEL assay is negative for apoptosis. Scale bar: 20 μm.
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was clear the thickness of the epithelium and eyelid
had been impacted by the treatment. Histologically
there was no evidence of cell loss in the stroma at any
time point, and the endothelium was intact through-
out. TUNEL staining did not show any evidence of
apoptosis (Fig. 5).
Discussion
In this study, we have developed a novel chemical
cross-linker that can be applied topically to the cornea
without removal of epithelium resulting in stiffening
of the cornea. We report here for the first time the
potential of a dicarboxylic acid cross-linker activated
by NHS/EDCI to produce clinically relevant stiffen-
ing of the cornea as a potential clinical treatment. In
conventional corneal cross-linking, the corneal epithe-
lium is removed to allow riboflavin to penetrate into the
stroma, then the cornea is exposed to UVA irradiation.
Riboflavin is a strong absorber of UVA, specifically at
the wavelengths used, and it is this increased absorp-
tion of UVA that causes cytotoxicity to the corneal
cells.17 Damage to keratocytes causes a pseudo-haze
in the cornea due to edema in the keratocyte lacunae
for three to four months after treatment.2 A very
important concern about the use of UVA is its toxicity
to the corneal endothelium. This means that conven-
tional treatment cannot be used in keratoconus patients
with thin corneas and given that keratoconus is a
corneal thinning disorder, andmany patients are identi-
fied at the later stages of the condition, particularly in
the developing world, withholding conventional treat-
ment to halt disease progression on the basis of corneal
thickness is a significant clinical problem, and these
patients are likely to go on to require corneal transplan-
tation.
The importance of our study is that the cross-
linking treatment stiffens the ex vivo cornea to the same
extent as the UVA-riboflavin conventional treatment
with a treatment time of 15minutes and that it does not
require removal of the epithelium and lower toxicity
to corneal cells. We believe this would make the treat-
ment applicable to a greater proportion of patients,
particularly those withmore advanced disease and thus
thinner cornea. As the cross-linker is applied to the
cornea, it will begin to interact with the proteins as it
diffuses into the tissue. As cross-links form, they will
stiffen the tissue, which could also reduce the rate of
diffusion further into the stroma. In this way the likeli-
hood of the cross-linker reaching the corneal endothe-
lium is reduced, thus protecting it from damage. We
used a fluorescently-tagged NHS and demonstrated its
penetration deep into the corneal tissue through the
intact epithelium (Supplementary Fig. S2). Although
the fluorescein-NHS is not the same as the cross-linker
they both have NHS-ester linkages that will interact
with primary amines in the tissue and so provide a
realistic representation of the likely penetration of the
cross-linker that can be visualized.
Similar to previously published literature,2,17 the
UVA/riboflavin-treated porcine cornea had evidence of
a lack of stromal cells in the uppermost section of the
tissue, suggesting the treatment had killed the cells. In
our treatments, keratocyte cell death was not observed
either by H&E or TUNEL staining in ex vivo porcine
and human corneas, as well as in the in vivo rabbit
corneas. Furthermore, outgrowth of stromal cells from
treated explants, specifically human and keratoconic
tissue, confirms the survival of the keratocytes after the
chemical cross-linking treatment.
The cross-linker solution has an acidic pH during
the course of treatment of the corneas (Supplemen-
tary Fig. S6), and we believe it is the low pH that
caused discomfort for the rabbits, swelling of the eye
lids and thinning of the corneal epithelium; however, at
no point was a full thickness epithelial defect observed.
Other eye drops, for example for glaucoma treatment,
have a pH in the 4-7.4 range.18 There is, however, an
opportunity to raise the pH of the cross-linker closer
to seven and still cause cross-linking within the tissue,
to reduce discomfort in in vivo conditions. EDCI is
known to be most effective at forming esters at pH
4.5 to 7.219,20 and NHS is similarly known to function
most effectively between pH 7.5 to 8.5.21 Therefore
at pH 7 both NHS and EDCI should still be able
to react with ODA and promote cross-linking. We
also intend to modify the treatment procedure in the
future using a dedicated corneal suction ring device
to limit the treatment solution to the central cornea
only and so protect the surrounding tissues. This would
also provide greater protection of the limbal epithelial
cells, which could increase the rate of epithelial healing
should thinning continue to occur.
Application of this cross-linker does not require
specialized equipment, such as that needed to deliver
UVA/riboflavin and thus in the longer term could
be used to treat patients within their local commu-
nity healthcare centers, rather than requiring trans-
port to hospital ophthalmology clinics. This could have
a significant bearing of the treatment of this sight-
threatening condition globally in low resource settings.
Demonstration of the ability to stiffen tissue in this
way could also have potential application in other
ocular conditions, for example, other reasons for loss
of corneal shape, inflammation in the eye caused by
infective, traumatic or immune-mediated corneal or
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scleral disorders, and mechanical strengthening of a
weakened sclera due to myopia22 or glaucoma.23 There
are published trials of using conventional cross-linking
protocol as an adjuvant therapy for treating fungal
keratitis along with the usual antifungal drugs,24,25
bullous keratopathy, and other corneal ectasias.10 Our
novel chemical cross-linker would be a promising
potential alternative to be used as an adjuvant therapy
for these disease conditions where survival of corneal
stromal cells would be a significant clinical advantage.
Other corneal cross-linking agents like 0.25% genipin26
or sodium hydroxymethylglycinate27 had a compara-
ble cross-linking efficiency to the conventional treat-
ment with minimal toxicity to endothelial cells in ex
vivo porcine and rabbit models. In all these trials,
the cross-linker was applied after epithelial debride-
ment. The conventional cross-linking protocol and its
modified accelerated protocols also formed a demarca-
tion line in the posterior cornea which was indicative of
keratocyte apoptosis observed in cross-linked human
corneas.8 A couple of cross-linkers were designed to be
applied without the removal of epithelium. Short chain
aliphatic beta nitro-alcohols exhibited less cytotoxic-
ity and cross-linked porcine corneal strips to a great
extent as measured by thermal shrinkage tempera-
ture compared with the standard treatment.28 Wang
et al.29 used EDCI, NHS and chondroitin sulphate
based cross-linker in an ex vivo rabbit model of kerato-
conus. The cross-linker could enhance the stiffness of
the cornea, restore collagen alignment without being
cytotoxic to keratocytes and the epithelium. We did
not observe keratocyte apoptosis in the stroma or a
demarcation line in the stroma after treatment with
our chemical cross-linker, and we observed no change
in the endothelial layer in porcine, rabbit, and human
corneas. It was clear, however, that the thickness of the
rabbit epithelium and eyelid had been impacted by the
treatment. Further work is needed to adjust the pH of
the formulation to closer to pH 7 and in the future
we intend to modify the procedure to use a dedicated
ring device to limit the treatment solution to the central
cornea alone to protect the surrounding tissues.
In conclusion, this study demonstrates for the first
time the potential of a dicarboxylic acid cross-linker
activated by NHS/EDCI to produce clinically relevant
stiffening of the cornea for treatment of keratoconus.
We show that the cross-linker can penetrate into the
corneal stroma without removal of the epithelium,
which will be a significant advantage for patient care.
We also demonstrate that it caused no histological
changes to ex vivo tissue and an initial in vivo study
demonstrated survival of the corneal cells in a rabbit
model. This treatment has several advantages over the
conventional UVA/riboflavin treatment in terms of
there being no need to physically remove the epithelium
and a lower toxicity throughout the cornea.
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